Skip to content

Study · Animal study (in vivo) · mouse · 2018

2 results

Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.

Elvert R, Herling AW, Bossart M, Weiss T, Zhang B, Wenski P, Wandschneider J, Kleutsch S, Butty U, Kannt A, Wagner M, Haack T and 5 more

Show all authors

Evers A, Dudda A, Lorenz M, Keil S, Larsen PJ

Diabetes, obesity & metabolism25 Jun 2018Cited by 33 (Europe PMC)

PMID29938884 (opens in a new tab)PMCIDPMC6055720 (opens in a new tab)DOI10.1111/dom.13212 (opens in a new tab)PepBankPUB-29938884
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, liraglutide affected glycaemic control similarly to a mouse-specific dual GLP-1R/GCGR agonist; the direction of change is not given in the abstract.

    In plain wordsIn mice, liraglutide changed blood sugar control in a way similar to a dual-acting drug.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedGlycaemic control in mice
    Study

    mousen: not reported in source

    Lean wild type, GLP-1R knockout and diet-induced obese mice
    Comparator
    Mouse-specific dual GLP-1R/GCGR agonist
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mouse-specific dual agonist and liraglutide similarly affected glycaemic control.
    1 context sentence
    Summary · context
    The mouse-specific dual agonist and liraglutide were tested in lean wild type, GLP-1R knockout and diet-induced obese mice at different doses.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese mice, liraglutide produced no effect on total energy expenditure, while a dual GLP-1R/GCGR agonist increased it.

    In plain wordsIn obese mice, liraglutide did not change total energy use, unlike a dual-acting drug that raised it.

    Peptide
    Liraglutide
    Outcome
    No significant changeTotal energy expenditure in diet-induced obese mice
    Study

    mousen: not reported in source

    Diet-induced obese mice
    Comparator
    Mouse-specific dual GLP-1R/GCGR agonist
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It increased TEE and enhanced fat and carbohydrate oxidation, while liraglutide produced no effect on TEE.
    1 context sentence
    Summary · context
    The mouse-specific dual agonist and liraglutide were tested in lean wild type, GLP-1R knockout and diet-induced obese mice at different doses.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.